 |
filgrastim |
|---|---|
| Trade Name | Neupogen |
| Orphan Indication | Subjects at risk of developing myelosuppression after a radiological or nuclear incident |
| USA Market Approval | USA |
| USA Designation Date | 2013-11-20 00:00:00 |
| Sponsor | Amgen, Inc.;One Amgen Center Drive, M/S 17-1-C;Thousand Oaks, California, 91320 |
